Medtronic plans to release its fiscal 4Q17 results on May 25, 2017.
In fiscal 3Q17, Medtronic’s revenue and earnings beat analysts’ estimates. Its revenue came in at $7.3 billion, representing a rise of ~5%, YoY (year-over-year). This rise included the ~1% impact of currency headwinds. The company’s CVG (Cardiac and Vascular Group), MITG (Minimally Invasive Therapies Group), and RTG (Restorative Therapies Group) segments registered mid-single-digit rises, whereas the Diabetes segment saw a rise in the high single digits.
